% | $
Quotes you view appear here for quick access.

P L C SYSTEMS AŞ Message Board

  • hermcz3 hermcz3 Nov 10, 2009 11:52 AM Flag

    WHO Does An About-Face

    How convenient that on the eve on PLCSF's earnings announcement, the WHO (World Health Organization) now says that AIDS and not heart disease is the #1 killer of women ages 15-44 years old.

    So rather than buy PLCSF stock, or grant them the funding and market cap necessary to further their research and penetration into conquering the perplexing problem of heart disease, the powers that be once again would rather sweep a very real problem under the rug and replace it with another.

    How suspicious that the article attesting to their change of heart (no pun intended) doesn't supply raw numbers, examples or statistics to support their argument.

    The reality does not change. Heart Disease is still the #1 killer of all Americans and people worldwide. It's just that no one wants to take responsibility for neglecting this particular company PLCSF, and consequently be blamed for allowing the deaths of over 50,000 Americans per month due to this ailment.

    A rebounding economy does not benefit an individual when he's buried six feet under due to a myocardial infarction.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Indeed. In the case of skin however, or any other exposed tissue--stimulation trumps injury. Better stated--regular mild stimulation therapy is more effective and less deleterious to the tissue than injury therapy.

      If the cardiac muscle (an intermix between striated involuntary and smooth) were an exposed organ. And the arteries were an exposed tissue, accessible to external impulses, then regular stimulation would be the therapy of choice to ensure long-term vialibily, tractibility, functionality and strength.

      But because the cardiac muscle is not exposed or accessible on a regular basis, a one time course of mild internal superficial injury is the option best suited to maintain its integrity.

      Again the ultimate aim here is to promote or induce evolutionary responses that work to benefit the organ's long-term survival and operation.

      Realistically speaking however, PLC Systems and CGCP being two companies in the forefront of the TMR experiment, being valued at less than $10m dollars, does not reflect adequate desire by the public for real advancements to be made on this front.

    • hermscz, what a paranoid post.
      And, since PLC has such low expectations for the role TMR is to play in its future, the post is irrelevant for PLC, as well as paranoid.

      • 1 Reply to participant42
      • <<<"Paranoid">>>

        I don't accept that premise. The data attesting to the efficacy of TMR is overly abundant. Management said in the CC that their biggest hurdle currently is finding a way to access funds to further their march towards basically conquering the problem of heart disease.

        Whether it be with TMR and/or Renal Guard. Both technologies work. The point at which we're at now is for waiting for the general and investing public to decide whether they want to support the technology and company, or not. The hospitals have already bought the equipment.

        It's very similar to when a doctor presents you with the options available to treat a particular medical condition. Doctors cannot, nor do they desire to, force treatment and technology onto an individual. The individual must eventually decide if they want to proceed foward with the treatment.

        So far, from the current stock price of PLCSF and CGCP (.22 and .19) the general public, or investing community is saying that they'd rather pass.

        So be it, but the 50,000 person monthly death toll of Americans from heart disease continues. An individual lives, or in this case, dies by the choices they make in life.